| Autor: |
Pablo, Gil-Perez, Juan Miguel, Ruiz-Nodar, María Asunción, Esteve-Pastor, Ignacio, Hortelano, Beatriz, Villamía, Nuria, Vicente-Ibarra, Esteban, Orenes-Piñero, Manuel Jesús, Macías, Laura, Núñez-Martínez, Luna, Carrillo, Elena, Candela, Andrea, Véliz-Martínez, Cecilia, López-García, Juan Gabriel, Martínez-Martínez, José Miguel, Rivera-Caravaca, Francisco, Marín |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Diabetes research and clinical practice. 184 |
| ISSN: |
1872-8227 |
| Popis: |
We investigated the impact of diabetes mellitus (DM) in acute coronary syndrome (ACS) patients, and the 2-year prognosis based on antiplatelet therapy.This is a prospective and multicenter registry including hospitalized ACS patients. Clinical management and antiplatelet therapy at discharge were recorded. Bleeding events, all-cause mortality and major adverse cardiovascular events (MACEs) were recorded during 2-years and compared according to DM and the P2YFrom 1717 ACS patients, 653 (38%) had DM. Diabetic patients were older, more commonly females, with higher prevalence of comorbidities and more conservative management. After excluding antiplatelet monotherapy or oral anticoagulation, clopidogrel was prescribed in 59.6% of DM patients. Cox regression analysis showed that DM was an independent risk factor for MACE (aHR 1.39, 95% CI 1.05-1.83). The use of clopidogrel instead of ticagrelor/prasugrel was also independently associated with MACE (aHR 1.71, 95% CI 1.11-2.63), and all-cause mortality (aHR 2.47, 95% CI 1.23-4.96) in diabetic patients (log-rank p-values 0.001).In ACS patients, DM was associated with higher risk of MACE. In such patients, the use of ticagrelor/prasugrel reduced MACE and mortality compared to clopidogrel. Novel P2Y |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect